Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind trial of ZEP-3 ointment versus acyclovir for recurrent herpes labialis
MOH_2017-08-22_000642Phase 2Completed
- Sponsor
- Shulov Innovative Science
- Start
- May 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in herpes labialis comparing ZEP-3 ointment with Acyclovir (Zovirax) (2 arms). Primary endpoints: Efficacy of treatment and Safety of treatment. Started May 2015; status: completed.
02
Drugs
ZEP-3aciclovir
03
Conditions
herpes labialis
Beyond the preview
Go deeper on MOH_2017-08-22_000642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-08-22_000642.